Atritech

TriMed Staff | | Cardiovascular Business | Patient Care
Atritech (Booth 1424) is featuring its Watchman Left Atrial Appendage (LAA) closure technology, for which the FDA recently accepted its pre-market approval application based on the data of the PROTECT AF trial.  

The Watchman LAA system is designed to keep harmful sized blood clots that form in the left atrial appendage from entering your blood stream, potentially causing stroke or other complications. It is designed to be permanently placed just behind or at the opening of the left atrial appendage.

TriMed Staff

Related Content

Concomitant ablation surgery during heart operations boosts long-term survival
Cardiologist explores why colchicine failed to help heart attack patients
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Most heart failure patients miss out on guideline-recommended palliative care
Cardiologist behind EARLY TAVR explains how proactive treatment improves patient outcomes
FDA approves Medtronic’s new all-in-one mapping and ablation system for AFib

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.